Physician profile
Vida Esfandiari
NPI 1558521435
$1,420.96
in general payments reported to CMS, 2019-2025
21 companies · $97.03 in 2025
The $97.03 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $50.30 · 2021: $182 · 2022: $383 · 2023: $317 · 2024: $200 · 2025: $97.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $413.68 | 2019-2023 | |
| Exeltis, USA INC. | $163.68 | 2019-2024 | Slynd |
| Organon LLC | $115.89 | 2022-2024 | Nexplanon |
| Astellas Pharma US INC | $86.76 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $81.21 | 2023-2025 | Omni Hysteroscope, Myosure Tissue Removal Device, Aptima |
| Sumitomo Pharma America, INC. | $73.73 | 2023-2024 | Myfembree |
| Biogen, INC. | $69.07 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $62.94 | 2021-2022 | |
| Bausch Health US, LLC | $58.78 | 2022-2023 | Aplenzin |
| Bayer Healthcare Pharmaceuticals INC. | $37.39 | 2019 | |
| Evofem Biosciences, INC. | $36.02 | 2021-2023 | Phexxi |
| Mayne Pharma Commercial LLC | $35.31 | 2025 | |
| Scynexis, INC. | $33.93 | 2022 | |
| Coopersurgical, INC. | $28.54 | 2022 | |
| Avanos Medical | $27.40 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $24.11 | 2019-2020 | |
| Becton, Dickinson and Company | $18.15 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.48 | 2019 | |
| Merck Sharp & Dohme LLC | $15.41 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.45 | 2019 | |
| Minerva Surgical, INC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vida Esfandiari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.